3Brain Company Profile

Background

Overview

3Brain is a pioneering biotechnology company specializing in advanced microelectrode array (MEA) technology for recording neural activity at high spatiotemporal resolution. Founded in 2011 and headquartered in Wädenswil, Zurich, Switzerland, 3Brain has been at the forefront of integrating microelectronics with biology to enhance scientific research in neuroscience, ophthalmology, and cardiology.

Mission and Vision

The company's mission is to revolutionize scientific research by developing microchip-based technologies that enable precise monitoring of neural activity. By providing high-resolution in vitro screening tools, 3Brain aims to accelerate the development of medical treatments and improve our understanding of brain functions.

Industry Significance

3Brain's innovative approach has significantly advanced the field of electrophysiology, offering researchers unprecedented insights into neural network dynamics. Their technology has been instrumental in various applications, including drug screening, disease modeling, and fundamental neuroscience research.

Key Strategic Focus

Core Objectives

3Brain focuses on developing and commercializing high-resolution MEA systems that enable real-time monitoring of neural activity. Their goal is to provide tools that enhance the accuracy and efficiency of in vitro experiments, thereby accelerating the discovery of new treatments for brain-related diseases.

Areas of Specialization

The company specializes in:

• High-Density Microelectrode Arrays (HD-MEAs): Platforms capable of recording from thousands of neurons simultaneously.

• CorePlate™ Technology: Multiwell devices designed for advanced cell-based analysis, featuring per-well logical processing cores.

Key Technologies Utilized

3Brain employs complementary metal-oxide-semiconductor (CMOS) technology to fabricate their MEA systems, enabling high-density electrode arrays with precise spatial resolution. This technology allows for the simultaneous recording of electrical signals from large neural networks, facilitating comprehensive analysis of neural activity.

Primary Markets Targeted

The company's products are primarily targeted at:

• Academic Research Institutions: For fundamental neuroscience studies.

• Pharmaceutical Companies: For drug discovery and toxicology testing.

• Biotech Firms: Developing treatments for neurological disorders.

Financials and Funding

Funding History

3Brain has secured funding through various channels, including grants and private investments. Specific details regarding total funds raised and recent funding rounds are not publicly disclosed. The company has received support from organizations such as Eurostars, indicating a strong foundation in the biotech community.

Utilization of Capital

The capital raised has been utilized to:

• Research and Development: Advancing the CorePlate™ technology and other product innovations.

• Product Manufacturing: Scaling up production capabilities to meet market demand.

• Market Expansion: Establishing a presence in key markets, including the United States.

Pipeline Development

Key Pipeline Candidates

3Brain's primary product in development is the CorePlate™ technology, a multiwell device designed for advanced cell-based analysis. This platform aims to provide high-resolution, real-time monitoring of neural activity, facilitating more accurate and efficient in vitro experiments.

Stages of Development

The CorePlate™ technology is in the final stages of development, with plans for commercialization in the near future. The company is collaborating with partners to validate and refine the product, ensuring it meets the needs of researchers and clinicians.

Target Conditions

The technology is designed to aid in the study and treatment of various neurological conditions, including:

• Neurodegenerative Diseases: Such as Alzheimer's and Parkinson's.

• Neurological Disorders: Including epilepsy and multiple sclerosis.

• Brain Injuries: Traumatic brain injuries and strokes.

Anticipated Milestones

Key milestones include:

• Product Launch: Introduction of CorePlate™ to the market.

• Regulatory Approvals: Obtaining necessary certifications for clinical use.

• Market Penetration: Establishing partnerships with academic and commercial entities.

Technological Platform and Innovation

Proprietary Technologies

3Brain's proprietary technologies include:

• CMOS-Based HD-MEAs: Enabling high-density, high-resolution neural recordings.

• CorePlate™ Technology: Multiwell devices with integrated processing cores for advanced cell analysis.

Significant Scientific Methods

The company employs advanced electrophysiological techniques, including:

• High-Density Electrode Arrays: For capturing detailed neural activity.

• Real-Time Data Processing: Facilitating immediate analysis of neural responses.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, the integration of advanced data processing and analysis methods suggests potential applications of AI in interpreting complex neural data.

Leadership Team

Key Executives

• Mauro Gandolfo, Ph.D.: Chief Executive Officer. Dr. Gandolfo has a background in neuroscience and has been instrumental in leading 3Brain's strategic direction.

• Alessandro Maccione, Ph.D.: Chief Scientific Officer. Dr. Maccione has extensive experience in electrophysiology and has contributed significantly to the development of 3Brain's technologies.

Leadership Changes

No recent significant changes or appointments within the company's leadership have been publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The market for advanced electrophysiology tools is growing, driven by increasing research in neuroscience and the need for precise in vitro models. Advancements in technology are enabling more detailed and scalable neural recordings, expanding the potential applications of these tools.

Competitor Analysis

Key competitors in the field include:

• Axion BioSystems: Offers MEA systems for neural recording and analysis.

• Molecular Devices: Provides a range of electrophysiology products, including MEA systems.

• Enzo Life Sciences: Supplies tools for cell biology research, including electrophysiology equipment.

Strategic Collaborations and Partnerships

In March 2021, 3Brain entered into a collaboration with a:head bio AG to develop the CorePlate™ technology. This partnership aims to enhance the capabilities of 3Brain's MEA systems and expand their applications in drug discovery.

Operational Insights

3Brain differentiates itself through its focus on high-resolution, high-density neural recording systems. The integration of CMOS technology allows for scalable and precise measurements, setting 3Brain apart from competitors.

Strategic Opportunities and Future Directions

Strategic Roadmap

3Brain plans to:

• Expand Product Offerings: Develop additional tools for neural recording and analysis.

• Enhance Technological Capabilities: Integrate advanced data processing and AI-driven analysis methods.

• Increase Market Penetration: Establish partnerships with academic institutions and pharmaceutical companies.

Future Business Directions

The company aims to become a leading provider of electrophysiology tools, supporting a wide range of research applications and contributing to advancements in neuroscience and related fields.

Opportunities for Expansion

Opportunities include:

• Geographic Expansion: Entering new international markets.

• Product Diversification: Developing complementary technologies for neural research.

• Strategic Partnerships: Collaborating with research institutions and industry leaders.

Positioning for Future Objectives